WHO ICTRP trial
REPRISE III: REpositionable Percutaneous Replacement of Stenotic Aortic Valve…
NL-OMON44639 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON44639 |
|---|---|
| Public title | REPRISE III: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus* Valve System - Randomized Clinical Evaluation |
| Scientific title | REPRISE III: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus* Valve System - Randomized Clinical Evaluation - REPRISE III |
| Primary sponsor | Boston Scientific Cooperation International |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | The Netherlands |
| Conditions | Narrowed aortic heart valve. Symptomatic aortic heart valve stenosis;10046973;10007593;Narrowed aortic heart valve.;Symptomatic aortic heart valve stenosis |
| Interventions | The randomized group will consist of two groups: One group will be eligible for TAVR with the Lotus Valve and the other group will be eligible for TAVR with the CoreValve. On average, 2 of every 3 patients will be in the Lotus group. The… |
| Registration date | May 30, 2016 |
| Target size | 20 |
| Secondary IDs | NL50236.078.14 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: